Anne Thomas

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Timothy Price, Marc Peeters, Tae Won Kim et al. · The Lancet Oncology · 2014 · 459 citations · Full text

Oncology, Chemotherapy-refractory Wild-type Kras, Colorectal Cancer +9

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Martin Dennis, Gillian Mead, John Forbes et al. · The Lancet · 2018 · 276 citations · Full text

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

Timothy Iveson, Ross C. Donehower, S. Tjulandin et al. · The Lancet Oncology · 2014 · 260 citations

Gastrointestinal Oncology, Medicine, Pathology +8

High-Level Clonal <i>FGFR</i> Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Alex Pearson, Elizabeth Smyth, Irina S. Babina et al. · Cancer Discovery · 2016 · 259 citations · Full text

A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

Jordi Rodón, Hussein Tawbi, Anne Thomas et al. · Clinical Cancer Research · 2014 · 228 citations · Full text